We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) trial.
- Authors
Jonas, Maureen M; Balistreri, William; Gonzalez-Peralta, Regino P; Haber, Barbara; Lobritto, Steven; Mohan, Parvathi; Molleston, Jean P; Murray, Karen F; Narkewicz, Michael R; Rosenthal, Philip; Schwarz, Kathleen B; Barton, Bruce A; Shepherd, John A; Mitchell, Paul D; Duggan, Christopher
- Abstract
Weight loss and changes in growth are noted in children treated with interferon alpha (IFN-α). The aim of this study was to prospectively determine changes in weight, height, body mass index (BMI), and body composition during and after treatment of children with hepatitis C virus (HCV). Children treated with pegylated interferon alpha-2a (Peg-IFN-α2a) ± ribavirin in the Pediatric Study of Hepatitis C (PEDS-C) trial underwent anthropometric measurements, dual-energy X-ray absorptiometry scan, as well as dietary and activity assessments during and after treatment. One hundred and fourteen (55% male) children, with a mean age of 11 ± 3 years, were randomized, and 107 received treatment for at least 24 weeks. Subjects were divided into three groups according to duration of treatment: 24 (N = 14), 48 (N = 82), or 72 (N = 11) weeks. Decrements of up to 0.50 z score were observed for weight, height, and BMI while on therapy among all groups (P ≤ 0.01, compared to baseline). In the group treated for 48 weeks, 29 (33%) subjects had greater than 0.5-unit decrement in height-for-age z (HAZ) score. Though weight-for-age and BMI z scores returned to baseline after cessation of therapy, mean HAZ score was slower to rebound, still lower than baseline at 96 weeks post-therapy for the long-treatment duration group (P = 0.03) and lower than baseline in most children treated for 48 weeks. Percent body fat, fat-free mass z scores, and triceps skinfold z scores decreased with therapy. Dietary energy intake and levels of physical activity did not change during treatment.
- Publication
Hepatology (Baltimore, Md.), 2012, Vol 56, Issue 2, p523
- ISSN
1527-3350
- Publication type
Journal Article
- DOI
10.1002/hep.25690